[Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D002845:Chromatography; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000009:adverse effects; D004298:Dopamine / Q000378:metabolism* / Q000502:physiology / Q000652:urine; D005116:Extrapyramidal Tracts / Q000503:physiopathology; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009420:Nervous System / Q000187:drug effects / Q000473:pathology; D009424:Nervous System Physiological Phenomena; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D014149:Tranquilizing Agents / Q000494:pharmacology
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D014149:Tranquilizing Agents; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D004298:Dopamine
Perturbations du métabolisme des catécholamines (notamment la dopamine) dans les syndromes parkinsoniens.